X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1533) 1533
Publication (291) 291
Paper (159) 159
Patent (109) 109
Report (70) 70
Book / eBook (64) 64
Book Review (10) 10
Book Chapter (5) 5
Data Set (3) 3
Conference Proceeding (2) 2
Newspaper Article (2) 2
Dissertation (1) 1
Magazine Article (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (551) 551
index medicus (467) 467
oncology (410) 410
female (400) 400
physics (256) 256
cern lhc coll (253) 253
experimental results (244) 244
breast cancer (216) 216
middle aged (211) 211
13000 gev-cms (208) 208
p p: scattering (198) 198
animals (197) 197
cancer (196) 196
adult (195) 195
aged (193) 193
experiment (188) 188
high energy physics - experiment (186) 186
p p: colliding beams (182) 182
breast neoplasms - drug therapy (181) 181
particle physics (159) 159
physics - high energy physics - experiment (158) 158
high energy physics (156) 156
hep (154) 154
chemotherapy (148) 148
breast neoplasms - pathology (144) 144
male (144) 144
trastuzumab (137) 137
article (125) 125
cms (125) 125
treatment outcome (125) 125
research (116) 116
antineoplastic combined chemotherapy protocols - therapeutic use (111) 111
phenomenology (111) 111
antineoplastic agents - therapeutic use (109) 109
mice (107) 107
analysis (105) 105
therapy (99) 99
chemistry (95) 95
mutation (93) 93
tumors (93) 93
human necessities (91) 91
hygiene (91) 91
medical or veterinary science (91) 91
cell line, tumor (89) 89
preparations for medical, dental, or toilet purposes (89) 89
metallurgy (87) 87
care and treatment (86) 86
physics of elementary particles and fields (83) 83
receptor, erbb-2 - metabolism (82) 82
organic chemistry (81) 81
breast neoplasms - metabolism (80) 80
peptides (80) 80
background (77) 77
breast neoplasms - genetics (76) 76
aged, 80 and over (74) 74
antineoplastic agents - pharmacology (74) 74
metastasis (74) 74
cell biology (72) 72
neoplasms - drug therapy (71) 71
testing (71) 71
hadron-hadron scattering (70) 70
investigating or analysing materials by determining theirchemical or physical properties (70) 70
measuring (70) 70
scattering [p p] (70) 70
[phys.hexp]physics [physics]/high energy physics - experiment [hep-ex] (67) 67
ecology (66) 66
ex (65) 65
genetic aspects (65) 65
monoclonal-antibody (65) 65
drug therapy (64) 64
colliding beams [p p] (63) 63
survival (62) 62
antibodies, monoclonal - therapeutic use (61) 61
antibodies, monoclonal, humanized (61) 61
health aspects (61) 61
disease-free survival (60) 60
prognosis (60) 60
expression (59) 59
signal transduction (56) 56
growth (55) 55
neoplasm metastasis (55) 55
nuclear experiment (55) 55
dose-response relationship, drug (54) 54
her2 (54) 54
proteins (53) 53
cern lab (52) 52
mass dependence (52) 52
biochemistry & molecular biology (51) 51
epidermal growth factor (51) 51
receptor, epidermal growth factor - antagonists & inhibitors (51) 51
drug administration schedule (50) 50
cells (49) 49
growth-factor receptor (49) 49
specific therapeutic activity of chemical compounds ormedicinal preparations (49) 49
channel cross section: upper limit (48) 48
gene expression (48) 48
neoplasm staging (48) 48
patients (48) 48
antineoplastic combined chemotherapy protocols - adverse effects (47) 47
cetuximab (47) 47
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
UTL at Downsview - May be requested (37) 37
Robarts - Stacks (19) 19
Collection Dvlpm't (Acquisitions) - Vendor file (6) 6
Pontifical Inst. Mediaeval Studies - Library use only (6) 6
St. Michael's College (John M. Kelly) - 3rd Floor (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Gerstein Science - Stacks (1) 1
Robarts - May be requested in 6-10 wks (1) 1
Robarts - Reference (1) 1
Robarts - Storage (1) 1
Scarborough Hospital - Online (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1675) 1675
Spanish (117) 117
French (39) 39
German (18) 18
Portuguese (17) 17
Korean (7) 7
Chinese (6) 6
Japanese (3) 3
Catalan (2) 2
Croatian (2) 2
Danish (2) 2
Greek (2) 2
Slovenian (2) 2
Latin (1) 1
Romance (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Oncologist, ISSN 1083-7159, 01/2011, Volume 16, Issue Supplement 1, pp. 12 - 19
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 8, pp. 726 - 736
Journal Article
Science, ISSN 0036-8075, 5/2006, Volume 312, Issue 5777, pp. 1175 - 1178
One of the most exciting developments in cancer research in recent years has been the clinical validation of molecularly targeted drugs that inhibit the action... 
Molecules | Receptors | Chemotherapy | Exons | Antineoplastics | Medical genetics | Breast cancer | Perspectives | Genetic mutation | Tumors | Cancer | CELL LUNG-CANCER | ADJUVANT CHEMOTHERAPY | GROWTH-FACTOR RECEPTOR | SINGLE-AGENT | GEFITINIB | MULTIDISCIPLINARY SCIENCES | MONOCLONAL-ANTIBODY CETUXIMAB | MUTATIONS | INHIBITOR | HER2-POSITIVE BREAST-CANCER | CHRONIC MYELOID-LEUKEMIA | Humans | Receptor, ErbB-2 - metabolism | Antibodies, Monoclonal - therapeutic use | Drug Resistance, Neoplasm | Antineoplastic Agents - therapeutic use | Proto-Oncogene Proteins c-kit - metabolism | Antibodies, Monoclonal, Humanized | Protein-Tyrosine Kinases - genetics | Receptor, Epidermal Growth Factor - metabolism | Neoplasms - genetics | Receptor, ErbB-2 - antagonists & inhibitors | Receptors, Platelet-Derived Growth Factor - antagonists & inhibitors | Antibodies, Monoclonal - pharmacology | Neoplasms - enzymology | Piperazines - therapeutic use | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Neoplasms - drug therapy | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Receptors, Platelet-Derived Growth Factor - metabolism | Fusion Proteins, bcr-abl - antagonists & inhibitors | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Benzamides | Mutation | Fusion Proteins, bcr-abl - metabolism | Trastuzumab | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Oncology, Experimental | Analysis | Management | Research | Phosphotransferases
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2015, Volume 372, Issue 8, pp. 724 - 734
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 904 - 916
Summary Background Phosphatidylinositol 3-kinase (PI3K) pathway activation is a hallmark of endocrine therapy-resistant, hormone receptor-positive breast... 
Hematology, Oncology and Palliative Medicine | HETEROGENEITY | WOMEN | PALBOCICLIB | THERAPY | EXEMESTANE | ONCOLOGY | MUTATION | RESISTANCE | COMBINATION | AROMATASE INHIBITORS | PI3K INHIBITOR | Estradiol - analogs & derivatives | Humans | Middle Aged | Aminopyridines - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Response Evaluation Criteria in Solid Tumors | Alanine Transaminase - blood | Receptors, Estrogen - analysis | Fulvestrant | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Neoplasm Metastasis | Hyperglycemia - chemically induced | DNA, Neoplasm - blood | DNA Mutational Analysis | Exanthema - chemically induced | Postmenopause | Female | Morpholines - adverse effects | Aminopyridines - administration & dosage | Drug Eruptions - etiology | Double-Blind Method | Morpholines - administration & dosage | Estradiol - administration & dosage | Survival Rate | Signal Transduction - genetics | Breast Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Retreatment | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Aspartate Aminotransferases - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Biomarkers, Tumor - genetics | Receptor, ErbB-2 - analysis | Antimitotic agents | Medical colleges | Clinical trials | Product development | Breast cancer | Postmenopausal women | Hormones | Antineoplastic agents | Analysis
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 6, pp. 732 - 742
Summary Background The antibody–drug conjugate trastuzumab emtansine is indicated for the treatment of patients with HER2-positive metastatic breast cancer... 
Hematology, Oncology and Palliative Medicine | RECEPTOR | ONCOLOGY | PERTUZUMAB | DOCETAXEL | GUIDELINES | Capecitabine - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Response Evaluation Criteria in Solid Tumors | Antineoplastic Agents - therapeutic use | Hand-Foot Syndrome - etiology | Diarrhea - chemically induced | Young Adult | Breast Neoplasms - chemistry | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Lapatinib | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Maytansine - analogs & derivatives | Anemia - chemically induced | Survival Rate | Thrombocytopenia - chemically induced | Trastuzumab - administration & dosage | Breast Neoplasms, Male - drug therapy | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Breast Neoplasms, Male - chemistry | Disease-Free Survival | Retreatment | Taxoids - administration & dosage | Vomiting - chemically induced | Aspartate Aminotransferases - blood | Capecitabine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Quinazolines - adverse effects | Aged | Breast Neoplasms, Male - pathology | Receptor, ErbB-2 - analysis | Bridged-Ring Compounds - administration & dosage | Care and treatment | Breast cancer | Metastasis | Patient outcomes | Analysis
Journal Article